Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 9 (September)

1. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
   Br J Cancer, 93(5): 529-37. [Abstract] [Full-text]
2. Comparison of three fluid solutions for resuscitation in dengue shock syndrome.
   N Engl J Med, 353(9): 877-89. [Abstract] [Full-text]
3. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
   J Clin Oncol, 23(25): 6181-9. [Abstract] [Full-text]
4. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer.
   J Clin Oncol, 23(25): 6027-36. [Abstract] [Full-text]
5. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
   J Clin Oncol, 23(25): 6002-8. [Abstract] [Full-text]
6. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
   J Clin Oncol, 23(25): 5943-9. [Abstract] [Full-text]
7. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
   J Clin Oncol, 23(25): 5929-37. [Abstract] [Full-text]
8. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
   J Clin Oncol, 23(25): 5918-28. [Abstract] [Full-text]
9. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
   Br J Cancer, 93(5): 557-64. [Abstract] [Full-text]
10. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
    Br J Cancer, 93(5): 510-4. [Abstract] [Full-text]
11. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.
    Br J Cancer, 93(5): 515-9. [Abstract] [Full-text]
12. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.
    J Clin Oncol, 23(25): 5910-7. [Abstract] [Full-text]
13. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    J Clin Oncol, 23(25): 5973-82. [Abstract] [Full-text]
14. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
    J Clin Oncol, 23(25): 6117-25. [Abstract] [Full-text]
15. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
    J Clin Oncol, 23(25): 5983-92. [Abstract] [Full-text]
16. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
    J Clin Oncol, 23(25): 5883-91. [Abstract] [Full-text]
17. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    J Clin Oncol, 23(25): 5892-9. [Abstract] [Full-text]
18. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    J Clin Oncol, 23(25): 5900-9. [Abstract] [Full-text]
19. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study.
    Pediatr Blood Cancer, 45(5): 644-8. [Abstract] [Full-text]
20. Histologic survey of neuroblastomas after intensive induction chemotherapy.
    Pediatr Blood Cancer, 45(5): 656-62. [Abstract] [Full-text]
21. Can we develop neurally acting drugs for the treatment of migraine?
    Nat Rev Drug Discov, 4(9): 741-50. [Abstract] [Full-text]
22. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy.
    Am J Ophthalmol, 140(3): 416-25. [Abstract] [Full-text]
23. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma.
    Am J Ophthalmol, 140(3): 397-406. [Abstract] [Full-text]
24. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Dis Colon Rectum, 48(9): 1742-51. [Abstract] [Full-text]
25. Gemcitabine plus paclitaxel in breast cancer.
    Semin Oncol, 32(4): S14-21. [Abstract] [Full-text]
26. Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
    Semin Oncol, 32(4): S9-13. [Abstract] [Full-text]
27. Gemcitabine and carboplatin in second-line ovarian cancer.
    Semin Oncol, 32(4): S4-8. [Abstract] [Full-text]
28. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas.
    Cancer, 104(6): 1281-7. [Abstract] [Full-text]
29. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.
    Cancer, 104(6): 1204-12. [Abstract] [Full-text]
30. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    J Natl Cancer Inst, 97(17): 1262-71. [Abstract] [Full-text]
31. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
    Jpn J Clin Oncol, 35(8): 433-8. [Abstract] [Full-text]
32. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hematol Oncol, 22(4): 159-68. [Abstract] [Full-text]
33. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    N Engl J Med, 353(10): 988-98. [Abstract] [Full-text]
34. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    N Engl J Med, 353(10): 977-87. [Abstract] [Full-text]
35. Postmenopausal bleeding on hormone replacement therapy: review of the current referral guidelines.
    J Obstet Gynaecol, 24(8): 920-1. [Abstract] [Full-text]
36. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Eur J Haematol, 75(4): 355-8. [Abstract] [Full-text]
37. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy.
    J Clin Endocrinol Metab, 90(9): 5321-3. [Abstract] [Full-text]
38. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency.
    J Clin Endocrinol Metab, 90(9): 5146-55. [Abstract] [Full-text]
39. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome.
    J Clin Endocrinol Metab, 90(9): 5324-8. [Abstract] [Full-text]
40. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
    J Clin Oncol, 23(26): 6429-36. [Abstract] [Full-text]
41. State-of-the-art therapeutics: marginal-zone lymphoma.
    J Clin Oncol, 23(26): 6415-20. [Abstract] [Full-text]
42. Current treatment approaches for mantle-cell lymphoma.
    J Clin Oncol, 23(26): 6409-14. [Abstract] [Full-text]
43. State-of-the-art therapeutics: Hodgkin's lymphoma.
    J Clin Oncol, 23(26): 6400-8. [Abstract] [Full-text]
44. Treatment strategies in follicular lymphomas: current status and future perspectives.
    J Clin Oncol, 23(26): 6394-9. [Abstract] [Full-text]
45. State-of-the-art therapeutics: diffuse large B-cell lymphoma.
    J Clin Oncol, 23(26): 6387-93. [Abstract] [Full-text]
46. Identification and validation of novel therapeutic targets for multiple myeloma.
    J Clin Oncol, 23(26): 6345-50. [Abstract] [Full-text]
47. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    J Clin Oncol, 23(26): 6325-32. [Abstract] [Full-text]
48. New targeted approaches in chronic myeloid leukemia.
    J Clin Oncol, 23(26): 6316-24. [Abstract] [Full-text]
49. Direct energy delivery improves tissue perfusion after resuscitated shock.
    Surgery, 138(2): 195-203. [Abstract] [Full-text]
50. Transporters and drug therapy: implications for drug disposition and disease.
    Clin Pharmacol Ther, 78(3): 260-77. [Abstract] [Full-text]
51. A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice.
    Biochim Biophys Acta, 1725(2): 182-9. [Abstract] [Full-text]
52. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes.
    Biomaterials, 27(2): 271-80. [Abstract] [Full-text]
53. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release.
    Biomaterials, 27(2): 262-70. [Abstract] [Full-text]
54. Gas foamed open porous biodegradable polymeric microspheres.
    Biomaterials, 27(2): 152-9. [Abstract] [Full-text]
55. Future directions in multiple myeloma treatment.
    Acta Haematol, 114: 8-13. [Abstract] [Full-text]
56. Raf: a strategic target for therapeutic development against cancer.
    J Clin Oncol, 23(27): 6771-90. [Abstract] [Full-text]
57. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    J Clin Oncol, 23(27): 6747-55. [Abstract] [Full-text]
58. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.
    J Clin Oncol, 23(27): 6730-8. [Abstract] [Full-text]
59. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
    J Clin Oncol, 23(27): 6664-73. [Abstract] [Full-text]
60. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    J Clin Oncol, 23(27): 6549-55. [Abstract] [Full-text]
61. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    J Clin Oncol, 23(27): 6481-8. [Abstract] [Full-text]
62. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial.
    J Natl Cancer Inst, 97(18): 1366-76. [Abstract] [Full-text]
63. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study.
    Int J Cancer, 117(4): 662-6. [Abstract] [Full-text]
64. Medication use and control of urination among community-dwelling older adults.
    J Aging Health, 17(5): 661-74. [Abstract] [Full-text]
65. Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.
    Oncology, 69(2): 135-44. [Abstract] [Full-text]
66. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
    Oncology, 69(2): 130-4. [Abstract] [Full-text]
67. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
    Oncology, 69(2): 122-9. [Abstract] [Full-text]
68. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
    Oncology, 69(2): 117-21. [Abstract] [Full-text]
69. Photodynamic therapy for cervical intraepithelial neoplasia.
    Oncology, 69(2): 110-6. [Abstract] [Full-text]
70. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
    Leukemia, 19(10): 1831-4. [Abstract] [Full-text]
71. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
    Leukemia, 19(10): 1806-11. [Abstract] [Full-text]
72. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.
    Lancet, 366(9491): 1108-10. [Abstract] [Full-text]
73. Assessment of the feasibility of oral controlled release in an exploratory development setting.
    Drug Discov Today, 10(17): 1159-66. [Abstract] [Full-text]
74. Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease.
    Am J Kidney Dis, 46(4): 595-602. [Abstract] [Full-text]
75. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.
    J Aerosol Med, 18(3): 294-303. [Abstract] [Full-text]
76. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
    Growth Horm IGF Res, 15(5): 349-59. [Abstract] [Full-text]
77. Primary angiosarcoma of the ovary: a case report of Stage I disease.
    Gynecol Oncol, 99(1): 218-21. [Abstract] [Full-text]
78. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.
    Eur J Surg Oncol, 31(8): 917-23. [Abstract] [Full-text]
79. Italian paediatricians and off-label prescriptions: loyal to regulatory or guideline standards?
    Acta Paediatr, 94(6): 753-7. [Abstract] [Full-text]
80. Testosterone ethosomes for enhanced transdermal delivery.
    Drug Deliv, 12(5): 297-303. [Abstract] [Full-text]
81. Designing and testing of an effective oil-in-water microemulsion drug delivery system for in vivo application.
    Drug Deliv, 12(5): 267-73. [Abstract] [Full-text]
82. A novel method for selective delivery of drugs to the pulmonary arteries.
    Drug Deliv, 12(5): 261-5. [Abstract] [Full-text]
83. Modeling of drug release from bioerodible polymer matrices.
    Drug Deliv, 12(5): 251-9. [Abstract] [Full-text]
84. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
    Br J Cancer, 93(7): 763-9. [Abstract] [Full-text]
85. UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.
    Br J Cancer, 93(7): 770-3. [Abstract] [Full-text]
86. Side effects during chemotherapy predict tumour response in advanced colorectal cancer.
    Br J Cancer, 93(7): 744-8. [Abstract] [Full-text]
87. An evaluation of the initial distribution volume of glucose to assess plasma volume during a fluid challenge.
    Anesth Analg, 101(4): 1089-93, table of contents. [Abstract] [Full-text]
88. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies.
    Acta Derm Venereol, 85(4): 299-303. [Abstract] [Full-text]
89. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    J Clin Oncol, 23(28): 7178-87. [Abstract] [Full-text]
90. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    J Clin Oncol, 23(28): 7161-7. [Abstract] [Full-text]
91. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
    J Clin Oncol, 23(28): 7135-42. [Abstract] [Full-text]
92. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
    J Clin Oncol, 23(28): 7089-97. [Abstract] [Full-text]
93. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    J Clin Oncol, 23(28): 7081-8. [Abstract] [Full-text]
94. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
    J Clin Oncol, 23(28): 6999-7004. [Abstract] [Full-text]
95. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
    J Clin Oncol, 23(28): 6982-91. [Abstract] [Full-text]
96. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
    J Clin Oncol, 23(28): 6966-75. [Abstract] [Full-text]
97. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
    J Clin Oncol, 23(28): 6881-9. [Abstract] [Full-text]
98. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
    J Clin Oncol, 23(28): 6873-80. [Abstract] [Full-text]
99. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.
    J Clin Oncol, 23(28): 6865-72. [Abstract] [Full-text]
100. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
     J Clin Oncol, 23(28): 6976-81. [Abstract] [Full-text]
101. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
     J Clin Oncol, 23(28): 7013-23. [Abstract] [Full-text]
102. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
     J Clin Oncol, 23(28): 6957-65. [Abstract] [Full-text]
103. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
     J Clin Oncol, 23(28): 7024-31. [Abstract] [Full-text]
104. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
     J Clin Oncol, 23(28): 6908-18. [Abstract] [Full-text]
105. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
     J Clin Oncol, 23(28): 7050-9. [Abstract] [Full-text]
106. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
     Eur J Haematol, 75(5): 376-83. [Abstract] [Full-text]
107. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?
     Eur J Haematol, 75(5): 361-9. [Abstract] [Full-text]
108. Cortical allograft as a vehicle for antibiotic delivery.
     Acta Orthop, 76(4): 481-6. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.